<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047319</url>
  </required_header>
  <id_info>
    <org_study_id>MS-LAQ-302E</org_study_id>
    <secondary_id>2009-015815-42</secondary_id>
    <nct_id>NCT01047319</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis</brief_title>
  <official_title>A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled
      MS-LAQ-302 study according to the protocol and to evaluate the long-term safety, tolerability
      and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing
      multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the
    study drug in the relevant dose
  </why_stopped>
  <start_date type="Actual">May 27, 2010</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 up to 7.13 years</time_frame>
    <description>A treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Potentially Clinically Significant Abnormal Vital Signs</measure>
    <time_frame>Baseline (Day 0 for extension), Day 1 up to 7.13 years</time_frame>
    <description>Vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria:
Pulse rate: &gt;=120 and increase &gt;=30 beats/minute
Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg
Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg
Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg
Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg
Note that the change is compared to baseline,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</measure>
    <time_frame>Baseline (Day 0), Day 1 to 7.13 years</time_frame>
    <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study
Participants whose condition was not changed from baseline or was changed to a non-PCS value are included in the population count.
ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</measure>
    <time_frame>Baseline (Day 0), Day 1 to 7.13 years</time_frame>
    <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study
Participants whose condition was not changed from baseline or was changed to a non-PCS value are included in the population count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study</measure>
    <time_frame>Baseline (Day 0), Day 1 to 7.13 years</time_frame>
    <description>Shifts are presented as Baseline finding / Worse finding at anytime during the study.
Categories for findings are:
normal
abnormal, not clinically significant (Not CS)
abnormal, clinically significant (CS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1047</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Experimental: Laquinimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule containing 0.6 mg laquinimod to be administered orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laquinimod</intervention_name>
    <description>One capsule containing 0.6 mg laquinimod to be administered orally once daily.</description>
    <arm_group_label>Experimental: Laquinimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have completed the Termination visit of MS-LAQ-302 (completion of all
             Termination visit activities) according to the MS-LAQ-302 protocol.

          2. Women of child-bearing potential must practice an acceptable method of birth control
             [acceptable methods of birth control in this open label extension phase include:
             surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch
             (or hormone-releasing vaginal ring), long-acting injectable contraceptive, partner's
             vasectomy or double-barrier method (condom or diaphragm with spermicide)] during the
             study and up to 30 days after the last dose of the study drug..

          3. Subjects must be willing and able to comply with the protocol requirements for the
             duration of the study.

          4. Subjects must be able to comprehend, sign and date a written informed consent prior to
             entering the MS-LAQ-302E study.

        Exclusion Criteria:

          1. Premature discontinuation from the MS-LAQ-302 study, for any reason.

          2. Pregnancy [according to urine dipstick Î²-HCG test performed at Baseline (Month 0E)
             visit] or breastfeeding.

          3. Subjects with clinically significant or unstable medical or surgical condition
             detected or worsened during the MS-LAQ-302 study, which preclude safe participation
             and completion of the MS-LAQ-302E study. Acute exacerbation of MS will not exclude
             participation in the MS-LAQ-302E study.

          4. Use of inhibitors of CYP3A4 within 2 weeks prior to baseline visit (V0E, Month 0E).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Timothy Vollmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 1267</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1237</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1279</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1276</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1272</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1238</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1280</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1282</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1275</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1250</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1260</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1263</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1269</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1273</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1264</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1261</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1245</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195-5244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1247</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1244</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1281</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1270</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 1253</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5914</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5915</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5917</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4212</name>
      <address>
        <city>Ruse</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5916</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5920</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5907</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5910</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5909</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5919</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5906</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5908</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5911</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5912</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5918</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5913</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4211</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6003</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6005</name>
      <address>
        <city>Varazdin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6001</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6002</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6006</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5419</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5418</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5420</name>
      <address>
        <city>Praha 5- Motol</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5421</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5508</name>
      <address>
        <city>Kohtla-Jarve</city>
        <zip>31025</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5507</name>
      <address>
        <city>Tallinn</city>
        <zip>EE-10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5509</name>
      <address>
        <city>Tartu</city>
        <zip>EE-51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8102</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8104</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8103</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6703</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6402</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6400</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8041</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8040</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262160</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3056</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3053</name>
      <address>
        <city>Cefalu</city>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3054</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3061</name>
      <address>
        <city>Empoli</city>
        <zip>50053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3049</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3055</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3048</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3052</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3050</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5708</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5707</name>
      <address>
        <city>Siauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6500</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6501</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6502</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5337</name>
      <address>
        <city>Bialystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5329</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5338</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6602</name>
      <address>
        <city>Gorzow Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5333</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5334</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5339</name>
      <address>
        <city>Katowice</city>
        <zip>40-684</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6603</name>
      <address>
        <city>Kielce</city>
        <zip>25-726</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 4213</name>
      <address>
        <city>Konskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5332</name>
      <address>
        <city>Koscierzyna</city>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5345</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5328</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5330</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-560</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5331</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5336</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5340</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5341</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5335</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5235</name>
      <address>
        <city>Balotesti</city>
        <zip>077015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5218</name>
      <address>
        <city>Bucharest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5214</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5213</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5215</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400012</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5217</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 8209</name>
      <address>
        <city>Craiova</city>
        <zip>200515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5216</name>
      <address>
        <city>Iasi</city>
        <zip>700661</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5219</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5043</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5033</name>
      <address>
        <city>Moscow</city>
        <zip>117152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5041</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5032</name>
      <address>
        <city>Moscow</city>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5038</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5042</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630117</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5035</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5037</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5036</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5034</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5044</name>
      <address>
        <city>Ufa</city>
        <zip>450007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6200</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6201</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6202</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6203</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9007</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9001</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9004</name>
      <address>
        <city>Johannesburg</city>
        <zip>2157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9003</name>
      <address>
        <city>Parktown- Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9008</name>
      <address>
        <city>Pietermaritzburg</city>
        <zip>3201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9005</name>
      <address>
        <city>Pretoria</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 9006</name>
      <address>
        <city>Rosebank</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3147</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3154</name>
      <address>
        <city>Figueres-Girona</city>
        <zip>17600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3149</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3152</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3151</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3148</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 3153</name>
      <address>
        <city>Tortosa-Tarragona</city>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 6503</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5823</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5811</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5812</name>
      <address>
        <city>Donetsk</city>
        <zip>83003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5814</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5817</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5818</name>
      <address>
        <city>Kharkiv</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5815</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5822</name>
      <address>
        <city>Kyiv</city>
        <zip>03110</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5809</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5820</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5821</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5810</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5819</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 5816</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <results_first_submitted>November 28, 2018</results_first_submitted>
  <results_first_submitted_qc>January 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2019</results_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT01047319/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants who completed the full duration of the double-blind BRAVO study (study MS-LAQ-302) were eligible to enter into Study MS-LAQ-302E. Of the 1090 participants who completed MS-LAQ-302, 1047 opted to continue into the open-label extension study.</recruitment_details>
      <pre_assignment_details>1047 subjects with RRMS were enrolled to receive laquinimod 0.6 mg daily at 144 study sites in 18 countries by 144 investigators.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Early Laquinimod</title>
          <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Switch From Placebo</title>
          <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
        </group>
        <group group_id="P3">
          <title>Switch From Avonex</title>
          <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="350"/>
                <participants group_id="P3" count="352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="345"/>
                <participants group_id="P2" count="350"/>
                <participants group_id="P3" count="352"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Teva requested participant withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants enrolled in the MS-LAQ-302 extension study.</population>
      <group_list>
        <group group_id="B1">
          <title>Early Laquinimod</title>
          <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Switch From Placebo</title>
          <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Switch From Avonex</title>
          <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="345"/>
            <count group_id="B2" value="350"/>
            <count group_id="B3" value="352"/>
            <count group_id="B4" value="1047"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.2" spread="9.16"/>
                    <measurement group_id="B2" value="40.1" spread="9.23"/>
                    <measurement group_id="B3" value="40.1" spread="9.34"/>
                    <measurement group_id="B4" value="39.8" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="707"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian/Oriental</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="338"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="348"/>
                    <measurement group_id="B4" value="1032"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>A treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest.</description>
        <time_frame>Day 1 up to 7.13 years</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Switch From Avonex</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>A treatment-emergent adverse event was defined as any untoward medical occurrence that develops or worsens in severity following start of treatment and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes. TEAEs associated with cancer, ischemic heart disease, cerebrovascular events, and arthritis were considered to be of special interest.</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>=&gt;1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="303"/>
                    <measurement group_id="O3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 TEAE causing discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 TEAE of special interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>=&gt;1 TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Potentially Clinically Significant Abnormal Vital Signs</title>
        <description>Vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria:
Pulse rate: &gt;=120 and increase &gt;=30 beats/minute
Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg
Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg
Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg
Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg
Note that the change is compared to baseline,</description>
        <time_frame>Baseline (Day 0 for extension), Day 1 up to 7.13 years</time_frame>
        <population>Safety analysis set of participants with a baseline and post-baseline value for that vital sign,</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Switch From Avonex</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Potentially Clinically Significant Abnormal Vital Signs</title>
          <description>Vital signs with potentially clinically significant abnormal results were evaluated using the following significance criteria:
Pulse rate: &gt;=120 and increase &gt;=30 beats/minute
Systolic blood pressure low: &lt;=90 and decrease &gt;=30 mmHg
Systolic blood pressure high: &gt;=180 and increase &gt;=30 mmHg
Diastolic blood pressure low: &lt;=50 and decrease &gt;=20 mmHg
Diastolic blood pressure high: &gt;=100 and increase &gt;=20 mmHg
Note that the change is compared to baseline,</description>
          <population>Safety analysis set of participants with a baseline and post-baseline value for that vital sign,</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least one abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse rate - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure - high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
        <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study
Participants whose condition was not changed from baseline or was changed to a non-PCS value are included in the population count.
ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</description>
        <time_frame>Baseline (Day 0), Day 1 to 7.13 years</time_frame>
        <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Switch From Avonex</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serum Chemistry Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
          <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study
Participants whose condition was not changed from baseline or was changed to a non-PCS value are included in the population count.
ALT=alanine aminotransferase ALP=alkaline phosphatase P-amylase=amylase, pancreatic AST=aspartate aminotransferase CRP=C reactive protein CK=creatine kinase CTN=creatinine FIB=fibrinogen GGT=gamma glutamyl transferase K=potassium</description>
          <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumen - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-Amylase - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTN - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FIB - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate-change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate-change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
        <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study
Participants whose condition was not changed from baseline or was changed to a non-PCS value are included in the population count.</description>
        <time_frame>Baseline (Day 0), Day 1 to 7.13 years</time_frame>
        <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Switch From Avonex</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serum Hematology Laboratory Tests That Were Potentially Clinically Significant (PCS) Abnormal Comparing Baseline to Any Time During the Study</title>
          <description>Counts include two conditions:
a change from High / Non-PCS at baseline to Low PCS at any point during the study
a change from Low / Non-PCS at baseline to High PCS at any point during the study
Participants whose condition was not changed from baseline or was changed to a non-PCS value are included in the population count.</description>
          <population>Safety analysis set of participants with both a baseline and a post-baseline value for the test.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="349"/>
                <count group_id="O3" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin -change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils - change from High/Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - change from High / Non-PCS to Low PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets - change from Low / Non-PCS to High PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study</title>
        <description>Shifts are presented as Baseline finding / Worse finding at anytime during the study.
Categories for findings are:
normal
abnormal, not clinically significant (Not CS)
abnormal, clinically significant (CS)</description>
        <time_frame>Baseline (Day 0), Day 1 to 7.13 years</time_frame>
        <population>Safety analysis set of participants with both a baseline and a post-baseline ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Laquinimod</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Switch From Placebo</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
          </group>
          <group group_id="O3">
            <title>Switch From Avonex</title>
            <description>All participants in MS-LAQ-302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Electrocardiogram (ECG) Fiindings That Shifted From Baseline to Any Time During the Study</title>
          <description>Shifts are presented as Baseline finding / Worse finding at anytime during the study.
Categories for findings are:
normal
abnormal, not clinically significant (Not CS)
abnormal, clinically significant (CS)</description>
          <population>Safety analysis set of participants with both a baseline and a post-baseline ECG.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="346"/>
                <count group_id="O3" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Normal / Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal / Abnormal, Not CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal / Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Not CS / Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Not CS / Abnormal, Not CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, Not CS / Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS / Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS / Abnormal, Not CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS / Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to 7.13 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early Laquinimod</title>
          <description>All participants in MS-LAQ- 302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Early laquinimod subgroup included participants in MS-LAQ-302 double-blind study who were administered laquinimod 0.6 mg daily for 24 months.</description>
        </group>
        <group group_id="E2">
          <title>Switch From Placebo</title>
          <description>All participants in MS-LAQ- 302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped.
The Switch from Placebo subgroup included participants in MS-LAQ-302 double-blind study who were administered placebo daily for 24 months.</description>
        </group>
        <group group_id="E3">
          <title>Switch From Avonex</title>
          <description>All participants in MS-LAQ- 302E were administered 1 capsule containing laquinimod 0.6 mg taken orally at the same hour every day until the product was commercially available or development stopped. The Switch from Avonex subgroup included participants in MS-LAQ-302 rater-blind study who were administered Avonex 30 mcg IM once weekly for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to metals</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chorioretinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Epiphyseal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ureteric injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Jaw cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Mood disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Crush syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Vaginal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bartholin's cyst removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fracture reduction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Radical hysterectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin lesion excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Splenectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Internal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="350"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="345"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="350"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="345"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="350"/>
                <counts group_id="E3" subjects_affected="194" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="345"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="350"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="24" subjects_at_risk="345"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="350"/>
                <counts group_id="E3" events="27" subjects_affected="16" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="345"/>
                <counts group_id="E2" events="38" subjects_affected="25" subjects_at_risk="350"/>
                <counts group_id="E3" events="32" subjects_affected="22" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="96" subjects_affected="52" subjects_at_risk="345"/>
                <counts group_id="E2" events="77" subjects_affected="46" subjects_at_risk="350"/>
                <counts group_id="E3" events="58" subjects_affected="37" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="345"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="350"/>
                <counts group_id="E3" events="15" subjects_affected="11" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="345"/>
                <counts group_id="E2" events="24" subjects_affected="15" subjects_at_risk="350"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="62" subjects_affected="36" subjects_at_risk="345"/>
                <counts group_id="E2" events="63" subjects_affected="36" subjects_at_risk="350"/>
                <counts group_id="E3" events="59" subjects_affected="28" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="345"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="350"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="350"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="345"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="350"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="345"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="350"/>
                <counts group_id="E3" events="38" subjects_affected="28" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="74" subjects_affected="49" subjects_at_risk="345"/>
                <counts group_id="E2" events="72" subjects_affected="49" subjects_at_risk="350"/>
                <counts group_id="E3" events="73" subjects_affected="50" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="84" subjects_affected="44" subjects_at_risk="345"/>
                <counts group_id="E2" events="121" subjects_affected="60" subjects_at_risk="350"/>
                <counts group_id="E3" events="128" subjects_affected="74" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="345"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="350"/>
                <counts group_id="E3" events="21" subjects_affected="17" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="345"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="350"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsorâs review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsorâs designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Pharmaceutical Industries, Ltd</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

